Topics
Researcher Hamada from DMPK BU to Present a Poster at the 52nd Annual Meeting of the Japanese Society of Toxicology
2025.06.24
Our researcher, Teruki Hamada from the DMPK Business Unit, will present a poster at the 52nd Annual Meeting of the Japanese Society of Toxicology, to be held from July 2 to 4, 2025, at the Okinawa Convention Center in Japan.
If you plan to attend the conference, we encourage you to join the session and hear the presentation.
Conference Name: the 52nd Annual Meeting of the Japanese Society of Toxicology
Date & Time: Friday, July 4th, 13:30pm – 14:30pm (JST)
Location: Okinawa Convention Center, Japan
Title: Evaluation of oral exposure increase for poorly soluble compounds with dissolution-improving formulations
Registration number: 5320
Presenter: Teruki Hamada, DMPK Business Unit
Presentation Summary
Poorly soluble compounds often fail to achieve the target plasma exposure in safety studies. Although solubilized and nanocrystal formulations may be prepared to improve the exposure, we cannot determine the most effective formulation before preparation. To address this issue, we have developed a workflow for improving exposure with solubilized and nanocrystal formulations by evaluating the plasma exposure of seven poorly soluble compounds in rats after oral administration.
Additionally, through detailed analysis of the results obtained from the intestinal absorption simulation software, we successfully estimated the improved exposure ratios of the compounds were using an intestinal absorption simulator. Our presentation will also include the rat toxicological profiles of the dosing vehicles used in this study.
Axcelead DDP’s Soulution
Axcelead DDP has extensive experience in physicochemistry / preformulation studies, pharmacokinetic analysis, and safety assessment, all of which are available as a one-stop package. If a poorly soluble compound is inadequately exposed in animals after oral administration, we can develop formulation to improve absorption. Even when solubility is not an issue, we can identify problems through various tests and analyses. Then, we can provide solutions, such as parenteral administration. Contact us if you are having trouble with insufficient plasma exposure of a compound in an in vivo study.
Teruki Hamada, DMPK Business Unit
After graduating from Graduate School of Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, The University of Tokyo, I worked for Takeda Pharmaceutical Industries, Ltd. before joining Axcelead DDP in 2017. I am involved in various research projects in the early stages of drug discovery as a DMPK representative. I specialize in translational research and modeling & simulation. Delegate of the Japanese Society for the Study of Xenobiotics.